Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
In development
Reference number: GID-TA10250
Expected publication date: TBC
Following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during early June 2020 when we will write to you about how you can get involved.